These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 888488)

  • 21. Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery.
    Breimer DD; Zilly W; Richter E
    Clin Pharmacol Ther; 1975 Oct; 18(4):433-40. PubMed ID: 1164825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of hepatic disease on the pharmacokinetics of famotidine and effects of famotidine on hepatic hemodynamics and peptic ulcer.
    Ohnishi K
    Hepatogastroenterology; 1990 Jul; 37 Suppl 1():6-10. PubMed ID: 2210613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 13CO2 excretion in breath of normal subjects and cirrhotic patients after 13C-aminopyrine oral load. Comparison with MEGX test in functional differentiation between chronic hepatitis and liver cirrhosis.
    Fasoli A; Giannini E; Botta F; Romagnoli P; Risso D; Celle G; Testa R
    Hepatogastroenterology; 2000; 47(31):234-8. PubMed ID: 10690614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation.
    Knodell RG; Dubey RK; Wilkinson GR; Guengerich FP
    J Pharmacol Exp Ther; 1988 Jun; 245(3):845-9. PubMed ID: 3385644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis of cirrhosis and hepatitis by quantitative hepatic and other reticuloendothelial clearance rates.
    DeNardo SJ; Bell GB; DeNardo GL; Carretta RF; Scheibe PO; Imperato TJ; Jackson PE
    J Nucl Med; 1976 Jun; 17(6):449-59. PubMed ID: 1262962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Aspects of bile acid metabolism in liver diseases(author's transl)].
    Horak W
    Acta Med Austriaca Suppl; 1975; 4():1-38. PubMed ID: 1064281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dipyrone metabolism in liver disease.
    Zylber-Katz E; Caraco Y; Granit L; Levy M
    Clin Pharmacol Ther; 1995 Aug; 58(2):198-209. PubMed ID: 7648770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Changes in renal function in patients with severe hepatitis and liver cancer with cirrhosis during orthotopic liver transplantation].
    Li XY; Hei ZQ; Li SR; Shen N
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Jul; 19(7):386-9. PubMed ID: 17631701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of liver disease on urine caffeine metabolite ratios.
    Denaro CP; Wilson M; Jacob P; Benowitz NL
    Clin Pharmacol Ther; 1996 Jun; 59(6):624-35. PubMed ID: 8681487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats.
    van der Graaff M; Vermeulen NP; Joeres RP; Vlietstra T; Breimer DD
    J Pharmacol Exp Ther; 1983 Nov; 227(2):459-65. PubMed ID: 6631725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Viral liver cirrhosis: natural course, pathogenesis and clinical implications of the complications].
    Gentilini P; Laffi G; La Villa G; Casini-Raggi V; Romanelli RG; Buzzelli G; Mazzanti R; Marra F; Pinzani M; Zignego AL
    Ann Ital Med Int; 1996 Oct; 11 Suppl 2():23S-29S. PubMed ID: 9004817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aminoacid imbalance ratio in liver disease.
    Maqsood R; Zuberi SJ
    J Pak Med Assoc; 1976 Jun; 26(6):145-6. PubMed ID: 826659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mesenchymal reaction and serum glycoprotein concentration in chronic hepatitis and liver cirrhosis.
    Fehér J; Jakab L; Józsa L; Szilvási I; Papp G
    Acta Morphol Acad Sci Hung; 1975; 23(4):319-26. PubMed ID: 1234831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum leptin levels in patients with nonalcoholic chronic liver disease.
    Nakamuta M; Tada S; Uchimura K; Enjoji M; Kinukawa N; Iwamoto H; Sugimoto R; Shimada M; Ohashi M; Sugimachi K; Nawata H
    Hepatogastroenterology; 2001; 48(38):527-32. PubMed ID: 11379347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.
    Chalasani N; Gorski JC; Patel NH; Hall SD; Galinsky RE
    Hepatology; 2001 Dec; 34(6):1103-8. PubMed ID: 11731998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of perinatal low protein diets on the ontogeny of select hepatic cytochrome p450 enzymes and cytochrome p450 reductase in the rat.
    Cherala G; Shapiro BH; D'mello AP
    Drug Metab Dispos; 2007 Jul; 35(7):1057-63. PubMed ID: 17392395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-order clearance of plasma galactose: the effect of liver disease.
    Henderson JM; Kutner MH; Bain RP
    Gastroenterology; 1982 Nov; 83(5):1090-6. PubMed ID: 7117792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternative transport pathways of cholephilic 14C-hexobarbital metabolites in rats with experimental hepatitis and cholestasis.
    Richter E; Joeres R; Buschmann J; Zilly W
    Acta Hepatogastroenterol (Stuttg); 1979 Dec; 26(6):429-34. PubMed ID: 549423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacokinetics of digoxin and methyldigoxin in patients with acute hepatitis (author's transl)].
    Zilly W; Richter E; Rietbrock N
    Med Klin; 1978 Mar; 73(13):463-9. PubMed ID: 634206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamic effects of furosemide in patients with liver cirrhosis.
    Traeger A; Häntze R; Penzlin M; Krombholz B; Reinhardt M; Keil E; Jorke D
    Int J Clin Pharmacol Ther Toxicol; 1985 Mar; 23(3):129-33. PubMed ID: 3997298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.